Selected article for: "clinical trial and disease drug"
Author: Zhang, Qiongshuai; Xu, Xiaohong; Sun, Shaoqian; Cao, Fang; Li, Jiannan; Qi, Xun; Ji, Guangcheng; Wang, Yufeng; Song, Bailin
Title: Efficacy of acupuncture and moxibustion in adjuvant treatment of patients with novel coronavirus disease 2019 (COVID-19): A protocol for systematic review and meta analysis
  • Cord-id: y1hevlxd
  • Document date: 2020_7_10
    • ID: y1hevlxd
    Snippet: BACKGROUND: Novel coronavirus has infected 4.33 million people in more than 200 countries in the current global outbreak of COVID-19. However, there is still no effective drug to treat the disease, and acupuncture and moxibustion is utilized as adjuvant therapy for the treatment of COVID-19 in China. METHODS: Nine electronic databases: PubMed, EMBASE, Cochrane library, Web of Science (WOS), Google Scholar, China National Knowledge Infrastructure (CNKI), Chinese Biomedical Literature Database (CB
    Document: BACKGROUND: Novel coronavirus has infected 4.33 million people in more than 200 countries in the current global outbreak of COVID-19. However, there is still no effective drug to treat the disease, and acupuncture and moxibustion is utilized as adjuvant therapy for the treatment of COVID-19 in China. METHODS: Nine electronic databases: PubMed, EMBASE, Cochrane library, Web of Science (WOS), Google Scholar, China National Knowledge Infrastructure (CNKI), Chinese Biomedical Literature Database (CBM), Chinese Scientific and Journal Database (VIP), Wan Fang database (Wanfang) and 2 clinical trials register platforms: Chinese Clinical Trial Registry (ChiCTR), ClinicalTrials.gov (www.ClinicalTrials.gov/) will be searched for RCTs of A&M for COVID-19. The screening process will be developed by 2 independent reviewers, and meta-analysis will be performed with RevMan (V5.3.5) software. RESULTS: The study results will be contributed to a scientific journal after peer-reviewed for publication. CONCLUSION: The study will provide up-to-date evidence of the effectiveness and safety of A&M for patients with COVID-19. PROSPERO REGISTRATION NUMBER: CRD42020185776

    Search related documents:
    Co phrase search for related documents
    • abstract title and acute ards respiratory distress syndrome: 1
    • abstract title and adjuvant therapy: 1
    • abstract title and adjuvant treatment: 1
    • acute ards respiratory distress syndrome and adjuvant therapy: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
    • acute ards respiratory distress syndrome and adjuvant treatment: 1, 2, 3, 4
    • acute ards respiratory distress syndrome and lung lesion: 1
    • acute ards respiratory distress syndrome and lung lesion absorption: 1
    • adjuvant therapy and low high moderate low: 1